Brambilla C, Zambetti M, Ferrari L, Bonadonna G
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
Tumori. 1989 Apr 30;75(2):141-4. doi: 10.1177/030089168907500212.
A combination of mitomycin C and vinblastine was administered as salvage treatment in 44 patients with heavily pretreated refractory breast cancer. Response rate was 23% (10 of 44) including one complete response of lung metastases. The highest response rate was seen in intrathoracic localizations (45%). Median duration of response was 6.5 months (range, 3+-17+). Treatment was generally well tolerated, and only 25% of patients developed nausea and vomiting. Neurologic toxicity was represented by paresthesia (8 patients) and constipation (one patient). Mild leukopenia was observed in 30 of 172 treatment cycles, but it exceeded grade 2 in only 5 patients. Considering the good compliance of this regimen and the poor prognosis of patients with advanced refractory disease, the combination of mitomycin C plus vinblastine appears to be useful as salvage treatment for metastatic breast cancer.
丝裂霉素C和长春碱联合用药作为挽救性治疗方案，应用于44例经过多次治疗的难治性乳腺癌患者。缓解率为23%（44例中有10例），其中1例肺转移患者获得完全缓解。胸腔内局部病变的缓解率最高（45%）。缓解持续时间的中位数为6.5个月（范围：3 +- 17 +）。该治疗总体耐受性良好，仅有25%的患者出现恶心和呕吐。神经毒性表现为感觉异常（8例患者）和便秘（1例患者）。在172个治疗周期中，有30例出现轻度白细胞减少，但仅有5例患者的白细胞减少超过2级。鉴于该方案的良好依从性以及晚期难治性疾病患者的预后较差，丝裂霉素C加长春碱联合用药似乎可作为转移性乳腺癌的挽救性治疗手段。
